LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 117 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2021. The put-call ratio across all filers is 0.40 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,557 | -92.6% | 6,404 | -91.1% | 0.00% | – |
Q2 2023 | $101,816 | -95.3% | 72,210 | -95.0% | 0.00% | – |
Q1 2023 | $2,165,669 | +179772.8% | 1,443,779 | +140208.9% | 0.00% | – |
Q4 2022 | $1,204 | +20.4% | 1,029 | +2.2% | 0.00% | – |
Q3 2022 | $1,000 | -94.4% | 1,007 | -90.8% | 0.00% | – |
Q2 2022 | $18,000 | +5.9% | 11,000 | 0.0% | 0.00% | – |
Q1 2022 | $17,000 | -80.2% | 11,000 | -68.8% | 0.00% | – |
Q4 2021 | $86,000 | +196.6% | 35,243 | +204.0% | 0.00% | – |
Q3 2021 | $29,000 | -40.8% | 11,592 | -33.5% | 0.00% | – |
Q2 2021 | $49,000 | -25.8% | 17,429 | -37.8% | 0.00% | – |
Q1 2021 | $66,000 | +187.0% | 28,021 | +116.1% | 0.00% | – |
Q4 2020 | $23,000 | +91.7% | 12,964 | 0.0% | 0.00% | – |
Q3 2020 | $12,000 | -91.7% | 12,964 | -92.2% | 0.00% | – |
Q2 2020 | $145,000 | +1015.4% | 166,607 | +938.8% | 0.00% | – |
Q1 2020 | $13,000 | -43.5% | 16,039 | -37.0% | 0.00% | – |
Q4 2019 | $23,000 | -41.0% | 25,470 | -37.6% | 0.00% | – |
Q3 2019 | $39,000 | – | 40,805 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |